Mineralys Therapeutics Inc (NASDAQ: MLYS) announced that its Phase 3 Launch-HTN clinical trial was selected as one of nine studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE